AstraZeneca deals take CRISPR to its drug discovery heart
This article was originally published in Scrip
Executive Summary
AstraZeneca has leveraged its "open-innovation" approach to strike four deals in the ground-breaking CRISPR genome editing field, positioning it well against its pharma peers.